This research article analyzed data from 517 tumor and 59 normal lung adenocarcinoma tissues from the TCGA-LUAD datasets. The study also included in vitro experiments to understand how ADAM9 affects cancer cells and immune cells. Researchers found that high levels of ADAM9 were linked to an immunosuppressive environment with more M2 macrophages and neutrophils. This environment is often associated with worse patient outcomes.
The study grouped patients into high- and low-risk categories based on ADAM9 and other gene signatures. Those in the high-risk group showed significant differences in survival compared to the low-risk group. A tool combining ADAM9 with clinical features showed strong accuracy in predicting patient outcomes.
Lab experiments showed that reducing ADAM9 activity changed how macrophages behave. This change helped suppress the growth and movement of tumor cells by affecting the IL-6/STAT3 signaling pathway. The findings suggest ADAM9 plays a role in how the tumor interacts with the immune system. However, this was an observational study with lab work, not a clinical trial testing a treatment.